REMOVAB

This brand name is authorized in Estonia, Lithuania

Active ingredients

The drug REMOVAB contains one active pharmaceutical ingredient (API):

1 Catumaxomab UNII M2HPV837HO - CATUMAXOMAB

Catumaxomab is a trifunctional rat-mouse hybrid monoclonal antibody that is specifically directed against the epithelial cell adhesion molecule (EpCAM) and the CD3 antigen. The EpCAM antigen is overexpressed on most carcinomas. Due to catumaxomab’s binding properties, a concerted immunoreaction against tumour cells is induced which includes different mechanisms of action, resulting in destruction of tumour cells. Read about Catumaxomab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
REMOVAB Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX03	Catumaxomab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1413908, 1413919
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1037230, 1037231